This corroborates other prior findings including the failure of anti-androgen clinical trials and could help to explain why attempts to regulate AR signaling by competitively antagonizing androgen binding with anti-androgens or suppressing gonadal androgen synthesis in HCC may have failed to produce clinical benefit. The gene discussed is AR; the disease is hepatocellular carcinoma.